Larvol Delta - Adaptive-Biotechnologies-Announces-FDA-Acceptance-of-Genentechs-Investigational-New-Drug-Application-for-the-First-NeoantigenDirected-TCell-Therapy-Product-in-Oncology

1st Shared TruTCR based cell therapy - Roche

https://www.globenewswire.com/news-release/2023/05/09/2664318/0/en/Adaptive-Biotechnologies-Announces-FDA-Acceptance-of-Genentech-s-Investigational-New-Drug-Application-for-the-First-Neoantigen-Directed-T-Cell-Therapy-Product-in-Oncology.html

May 9, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next